Acrivon Therapeutics
web2Acrivon Therapeutics is an American clinical stage biotechnology company developing precision o...
About
Acrivon Therapeutics is an American clinical stage biotechnology company developing precision oncology medicines and diagnostic tests intended to identify patients likely to benefit from specific cancer treatments. Its proprietary AP3 platform analyzes protein signaling activity to investigate tumor biology and support drug development and patient selection. The lead candidate, ACR368, also known as prexasertib, inhibits checkpoint kinases involved in cellular responses to DNA damage and is being evaluated in clinical trials. Acrivon also develops ACR2316, targeting the WEE1 and PKMYT1 kinases, and the investigational CDK11 inhibitor ACR7280. Its therapeutic programs remain subject to clinical development and regulatory evaluation.
Explore this sector
Exchange listings
Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.
Acrivon Therapeutics profile.
Expert coverage
No published expert evaluations are available for this project yet.
Orbitrum Academy